A phase II randomized study of the combination of Ribociclib plus goserelin acetate with Hormonal Therapy versus physician choice chemotherapy in premenopausal or perimenopausal patients with hormone receptorpositive/HER2-negative inoperable locally advanced or metastatic breast cancer – RIGHT Choice Study.

drug protocol number
CLEE011A3201C
drug sponsor
Novartis
drug study
ribociclib
drug trial site
King Faisal Specialist Hospital and Research Center (Riyadh)
drug status
Terminated
drug phase